For the quarter ending 2026-03-31, PTGX had $65,323K increase in cash & cash equivalents over the period. -$49,158K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 56,368 | 7,437 | 4,712 | - |
| Discovery department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 8,506 | 9,110 | 21,410 | - |
| Development department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 17,473 | 18,685 | 75,711 | - |
| General and administrative expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 5,695 | 5,899 | 28,927 | - |
| Employee wages and benefits - discovery | 3,148 | 2,930 | 11,464 | - |
| Employee wages and benefits - development | 5,952 | 5,986 | 25,548 | - |
| Employee wages and benefits - general and administrative | 4,723 | 4,481 | 18,522 | - |
| Stock-based compensation expense | 14,519 | 10,701 | 59,987 | - |
| Other segment items | -53 | 124 | -269 | - |
| Interest income | 5,876 | 6,761 | 7,049 | - |
| Income tax benefit | -1,502 | 666 | 344 | - |
| Net income (loss) | 3,783 | -44,384 | -39,339 | -46,426 |
| Stock-based compensation | 14,519 | 10,701 | 10,559 | 24,714 |
| Non-cash lease expense | 439 | 345 | 106 | 1,137 |
| Depreciation | 407 | 376 | 361 | 543 |
| Accretion of discount on marketable securities | 1,025 | 1,336 | 1,684 | 4,203 |
| Net realized loss on sale of marketable securities | - | - | 1 | -5 |
| Other | -2 | -8 | - | - |
| Contract asset | - | - | - | 22,287 |
| Receivable from collaboration partner | 53,542 | -462 | 583 | -165,000 |
| Income taxes payable | - | 0 | 0 | -2,689 |
| Prepaid expenses and other assets | 1,918 | 365 | -50 | 2,045 |
| Accounts payable | 3,003 | -307 | 2,418 | 1,612 |
| Accrued expenses and other payables | -10,792 | 5,409 | 7,545 | -8,378 |
| Deferred revenue | -3,268 | -7,438 | -3,075 | -10,504 |
| Operating lease liability | -547 | 1,380 | -581 | 104 |
| Net cash (used in) provided by operating activities | -48,943 | -36,975 | -1,937 | 96,583 |
| Purchase of marketable securities | 68,968 | 104,274 | 161,117 | 281,194 |
| Proceeds from maturities of marketable securities | 156,691 | 153,233 | 102,650 | 235,957 |
| Proceeds from sale of marketable securities | 3,384 | 0 | 0 | 7,003 |
| Purchases of property and equipment | 215 | 144 | 88 | 1,358 |
| Net cash provided by (used in) investing activities | 90,892 | 48,815 | -58,555 | -39,592 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 23,374 | 2,837 | 5,659 | 14,847 |
| Tax withholding payments related to net settlement of restricted stock units | - | 0 | 0 | 479 |
| Net cash provided by financing activities | 23,374 | 2,837 | 5,659 | 14,368 |
| Net increase in cash, cash equivalents and restricted cash | 65,323 | 14,677 | -54,833 | 71,359 |
| Cash, cash equivalents and restricted cash, beginning of period | 128,677 | 114,000 | 97,474 | - |
| Cash, cash equivalents and restricted cash, end of period | 194,000 | 128,677 | 114,000 | - |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)